Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
BOK Financial Corporation (BOKF) - free report >>
Agenus Inc. (AGEN) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BOK Financial Corporation (BOKF) - free report >>
Agenus Inc. (AGEN) - free report >>
Image: Bigstock
New Strong Buy Stocks for July 20th
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Agenus Inc (AGEN - Free Report) : This immuno-oncology (I-O) company has witnessed the Zacks Consensus Estimate for its current year earnings surging 10.2% over the last 30 days.
Agenus Inc. Price and Consensus
Agenus Inc. Price and Consensus | Agenus Inc. Quote
Alcobra Ltd : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings soaring 16.7% over the last 30 days.
Alcobra Ltd. Price and Consensus
Alcobra Ltd. Price and Consensus | Alcobra Ltd. Quote
BOK Financial Corporation (BOKF - Free Report) : This financial holding company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.5% over the last 30 days.
BOK Financial Corporation Price and Consensus
BOK Financial Corporation Price and Consensus | BOK Financial Corporation Quote
Cellectis SA (CLLS - Free Report) : This company active in the field of genome engineering and genomic surgery has seen the Zacks Consensus Estimate for its current year earnings increasing 2.9% over the last 30 days.
Cellectis S.A. Price and Consensus
Cellectis S.A. Price and Consensus | Cellectis S.A. Quote
Chemours Co (CC - Free Report) : This provider of performance chemicals has witnessed the Zacks Consensus Estimate for its current year earnings improving 4.5% over the last 30 days.
Chemours Company (The) Price and Consensus
Chemours Company (The) Price and Consensus | Chemours Company (The) Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Want to see all of today's Zacks Strong Buys?
You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 stocks free of charge. There is no better place to start your own stock search. Plus you can also access the full list of must-avoid Zacks Strong Sells and other private research. See the stocks free >>.